MARKET

AVDL

AVDL

Avadel Pharmaceu
NASDAQ
12.62
+0.02
+0.16%
After Hours: 12.62 0 0.00% 16:00 02/23 EST
OPEN
12.68
PREV CLOSE
12.60
HIGH
13.05
LOW
12.48
VOLUME
1.53M
TURNOVER
0
52 WEEK HIGH
17.24
52 WEEK LOW
8.00
MARKET CAP
1.13B
P/E (TTM)
-5.8361
1D
5D
1M
3M
1Y
5Y
Avadel Pharmaceuticals (AVDL) Shares Cross Below 200 DMA
NASDAQ · 3d ago
Weekly Report: what happened at AVDL last week (0212-0216)?
Weekly Report · 5d ago
Weekly Report: what happened at AVDL last week (0205-0209)?
Weekly Report · 02/12 10:11
UBS Initiates Coverage On Avadel Pharmaceuticals with Buy Rating, Announces Price Target of $21
Benzinga · 02/06 12:45
Weekly Report: what happened at AVDL last week (0129-0202)?
Weekly Report · 02/05 10:15
Updated View On Jazz Pharmaceuticals' 2025 Goals
Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion. Despite this, the stock looks undervalued and has the potential to re-rate higher. The fears over the oxybate franchise's demise are overblown. The growth of Xywav, Rylaze, and Epidiolex and upcoming pipeline readouts are encouraging.
Seeking Alpha · 01/29 20:17
Weekly Report: what happened at AVDL last week (0122-0126)?
Weekly Report · 01/29 10:10
Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Seeking Alpha · 01/28 07:56
More
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Webull offers Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ: AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.